Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 327 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

327 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 327 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

327 programs

Clinical programs

Page 5 of 7

  1. Nicotrol

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 1 small molecule completed

    1 trial

  2. Nifedipine 60 MG Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. O2P-001

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Pain

    phase 1 small molecule active

    1 trial

  4. OROS-MPH

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

  5. Omnitram

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  6. Opioid Agonist

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 1 small molecule completed

    1 trial

  7. Oral methylphenidate and Oral haloperidol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 1 small molecule completed

    1 trial

  8. Original formulation EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  9. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  10. Outpatient MST/OPTION-A

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 other completed

    1 trial

  11. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  12. OxyCODONE 5 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    1 trial

  13. Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  14. Oxycodone IN

    BRIGHT MINDS BIOSCIENCES INC.

    Physiologically Based Pharmacokinetic

    phase 1 small molecule completed

    1 trial

  15. Oxycodone Medication First

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Drug Abuse (Not Dependent)

    phase 1 small molecule completed

    1 trial

  16. Oxycodone and Midazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercapnia

    phase 1 small molecule completed

    1 trial

  17. PA-824 1000 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  18. PA-824 200mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  19. PF614 solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  20. PRO 2000/5 Gel (P)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  21. Parotid Gland

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 other completed

    1 trial

  22. Part 1: Cream

    BRIGHT MINDS BIOSCIENCES INC.

    Systemic Exposure to Sunscreen Ingredients

    phase 1 small molecule completed

    1 trial

  23. Peptides (N,R&C) formulated in Montanide ISA 720

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 small molecule completed

    1 trial

  24. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

  25. Pharmacogenomics testing for clopidogrel responsiveness

    BRIGHT MINDS BIOSCIENCES INC.

    Stroke

    phase 1 other completed

    1 trial

  26. Pharmacy-based methadone administration and dispensing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  27. Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages

    BRIGHT MINDS BIOSCIENCES INC.

    Social Anxiety Disorder

    phase 1 other terminated

    1 trial

  28. Phenytoin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule completed

    1 trial

  29. Piracetam

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule terminated

    2 trials

  30. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    D-limonene and THC Pharmacodynamics

    phase 1 small molecule completed

    1 trial

  31. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule active

    1 trial

  32. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Addiction

    phase 1 small molecule completed

    1 trial

  33. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  34. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    THC

    phase 1 small molecule completed

    1 trial

  35. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule active

    1 trial

  36. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 1 small molecule active

    1 trial

  37. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Abuse

    phase 1 small molecule completed

    1 trial

  38. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Memory

    phase 1 small molecule completed

    1 trial

  39. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    2 trials

  40. Placebo Aprepitant

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Withdrawal

    phase 1 small molecule completed

    1 trial

  41. Placebo and Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercapnia

    phase 1 small molecule completed

    1 trial

  42. Placebo pills for 14-day intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Controls

    phase 1 small molecule active

    1 trial

  43. Pomaglumetad methionil

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 1 small molecule terminated

    1 trial

  44. Pramipexole

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Addiction

    phase 1 small molecule completed

    1 trial

  45. Pretomanid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  46. Progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 1 small molecule completed

    1 trial

  47. QRL-101 Dose A

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  48. Quercetin (dietary supplement)

    BRIGHT MINDS BIOSCIENCES INC.

    Fanconi Anemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

327 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.